Equities researchers at StockNews.com assumed coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) in a report issued on Friday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Stock Performance
Shares of Galmed Pharmaceuticals stock opened at $1.59 on Friday. Galmed Pharmaceuticals has a one year low of $1.38 and a one year high of $23.80. The stock has a 50 day moving average price of $2.37 and a 200-day moving average price of $3.36. The stock has a market cap of $1.02 million, a price-to-earnings ratio of -0.10 and a beta of 0.72.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC purchased a new position in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned 3.97% of Galmed Pharmaceuticals as of its most recent SEC filing. Institutional investors and hedge funds own 76.14% of the company’s stock.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Further Reading
- Five stocks we like better than Galmed Pharmaceuticals
- How to Short a Stock in 5 Easy Steps
- MarketBeat Week in Review – 03/24 – 03/28
- What is a Stock Market Index and How Do You Use Them?
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
- Dividend Capture Strategy: What You Need to Know
- 4 Healthcare Stocks With Massive Gains—and More to Come
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
